Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adult

Clinical Editorial

This study evaluates the cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease and potential effect on US health care spending.

Source Reference

Read the full original publication from the source journal or publisher link below.

Related by Condition/Drug

Cost-Effectiveness of Semaglutide for Secondary Prevention of Cardiovascular Disease in US Adult

Clinical Briefing

Clinical Editorial

Source Reference

Related by Condition/Drug